• Positive Phase I results for Allergy’s Acarovac pharmatimes
    May 21, 2019
    Allergy Therapeutics announced positive Phase I safety and tolerability results of its subcutaneous Acarovac MPL (Monophosphoryl Lipid A). The results were in patients with house dust mite-induced allergic rhinoconjunctivitis.
PharmaSources Customer Service